Navigation Links
Prostate cancer prognosis hope
Date:10/30/2012

Scientists have discovered a molecular 'tell' in laboratory experiments that could help doctors determine the severity of a patient's prostate cancer.

Cancer of the prostate the most common male cancer in the UK presents in two distinct ways: a low-risk type, which may never cause any symptoms, and a high-risk form that needs treatment to prevent it spreading to other parts of the body.

Knowing which type of prostate cancer each patient has some 40,000 British men per year is therefore essential to ensuring they receive the correct treatment.

Lead researcher Dr Angeliki Malliri, from the University of Manchester's Paterson Institute for Cancer Research, said: "Prognosis tells, or biomarkers, give doctors an indication of how a patient will fare after treatment. In prostate cancer, biomarkers that help differentiate between the low-risk and high-risk types of cancer are crucial to decide if and what type of treatment a patient needs."

The study, funded by Cancer Research UK and published in the journal Nature Cell Biology, identified the protein β2-syntrophin as a new prognosis marker for prostate cancer. The team, part of the Manchester Cancer Research Centre (MCRC), discovered that the protein is involved in establishing tight connections between cells, which are crucial for holding them together to maintain tissue structure and prevent tumours from spreading.

Co-author Dr Natalie Mack said: "We showed that when β2-syntrophin is lost from these cell-to-cell connections, the cells become disorganised and this is what happens in cells from prostate cancer samples, potentially helping them to spread.

"Our findings indicate that the loss of β2-syntrophin at cell-to-cell connections in the prostate is an indicator of prostate cancer progression and patients with reduced levels of this protein at these cell-to-cell connections are more likely to have a recurrence of their cancer after treatment."

The authors say their results suggest that β2-syntrophin is a new prognosis marker in prostate cancer and that it should be further explored to distinguish between low- and high-risk level disease. Improved understanding and use of prognosis markers is essential to help guide clinical decisions and to ensure that patients get the best type of treatment for their type of cancer.

Dr Julie Sharp, senior science information manager at Cancer Research UK, said: "To treat prostate cancer more effectively, we need to understand more about how the disease develops and how to recognise more advanced types. This research provides another piece of the puzzle and further work will confirm whether this molecule could be useful in making better predictions about prostate cancer."


'/>"/>

Contact: Aeron Haworth
aeron.haworth@manchester.ac.uk
44-161-275-8383
University of Manchester
Source:Eurekalert

Related medicine news :

1. Proton therapy treatment preserves quality of life for men with prostate cancer
2. For many prostate cancer patients, Web sites are too difficult to read
3. Viagra Can Help Prostate Cancer Patients Maintain Sex Lives: Study
4. Drop in testosterone tied to prostate cancer recurrence
5. Moffitt Researchers find genetic predictors of fatigue for some prostate cancer patients
6. First web-based prostate cancer database launches
7. Lab Contamination Behind Debunked Link Between Virus, Prostate Cancer
8. Researchers reveal underlying mechanism of powerful chemotherapy for prostate cancer treatment
9. Cloned receptor paves way for new breast and prostate cancer treatment
10. Drug Used to Prevent Prostate Cancer Wont Lower Quality of Life
11. Taking Breaks From Prostate Cancer Hormone Therapy Seems Safe: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new ... affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... , June 23, 2016 The vast ... an outpatient dialysis facility.  Treatments are usually 3 times ... hours per visit, including travel time, equipment preparation and ... patient, but especially grueling for patients who are elderly ... a skilled nursing and rehabilitation centers for some duration ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... rough waters, but it continues to present great opportunities ... featured companies for today: Intrexon Corp. (NYSE: ... ), Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), ... Learn more about these stocks and receive your complimentary ...
Breaking Medicine Technology: